| Number of deaths/years at risk | Mortality Rate Ratio1 (95% CI) (Low dose vs. Recommended dose) | |||
---|---|---|---|---|---|
 | Low dose | Recommended dose |  |  |  |
 | All (n = 8582) | All (n = 8582) | Boys (n = 4369) | Girls (n = 4213) | |
Age groups | |||||
6-11 months | 7/397 | 11/327 | 0.54 (0.21-1.38) | 0.39 (0.07-2.11) | 0.63 (0.20-1.99) |
12-17 months | 7/316 | 4/301 | 1.65 (0.48-5.63) | 1.34 (0.30-6.00) | 2.73 (0.28-26) |
18-60 months | 25/2763 | 17/2823 | 1.50 (0.81-2.77) | 1.97 (0.74-5.25) | 1.22 (0.54-2.72) |
P for same effect in age groups | Â | Â | 0.17 | 0.27 | 0.46 |
VAS at birth | |||||
 | All (n = 2295) | All (n = 2295) | Boys (n = 1182) | Girls (n = 1113) | |
VAS at birth | 5/308 | 3/260 | 1.30 (0.31-5.46) | 0.89 (0.05-15) | 1.50 (0.27-8.18) |
Placebo at birth | 2/289 | 6/251 | 0.29 (0.06-1.41) | 0.79 (0.05-13) | 0.18 (0.02-1.52) |
P for same effect by VAS at birth | Â | Â | 0.17 | 0.93 | 0.12 |